Seragon is focused on developing new treatments for estrogen-driven cancers based on its Selective Estrogen Receptor Degrader (SERD) platform
Seragon is focused on developing new treatments for estrogen-driven cancers based on its Selective Estrogen Receptor Degrader (SERD) platform. The company aims to create orally active SERDs that can effectively treat progressive metastatic breast cancer and overcome resistance to existing anti-hormonal therapies.